ArticleCancer medicine2025
Colorectal Cancer Screening Amid COVID-19 in Japan: Analysis From the 2021-2022 JACSIS Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Forecasting colorectal cancer screening in Japan: regional and sex disparities threaten national targets.International journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMaintaining a high participation rate is crucial for effective colorectal cancer (CRC) screening. The COVID-19 pandemic placed a significant burden on healthcare facilities, which hindered CRC screening efforts. However, the effects of the prolonged pandemic on CRC screening remain unclear.
methodsWe analyzed data from the Japan COVID-19 and Society Internet Survey in September 2021 and 2022 to examine CRC screening participation over the past year. We also evaluated the association between CRC screening participation in 2022 and the participation status, future screening intentions, background characteristics, and anxiety about COVID-19 measured using the fear of coronavirus disease 2019 scale (FVC-19S) from the 2021 survey..
resultsOf the 13,261 respondents, 40.5% reported undergoing CRC screening in 2021, while 48.7% did so in 2022. Multivariable Poisson regression analysis showed that significant factors associated with CRC screening participation in 2022 included being male (adjusted incidence risk ratio [aIRR] 1.07, 95% confidence interval [CI]; 1.00-1.14, p = 0.026), age in the 40s (aIRR 0.89, 95% CI; 0.81-0.97, p = 0.012) and 50s (aIRR 0.89, 95% CI; 0.82-0.98, p = 0.011), being unmarried (aIRR 0.88, 95% CI; 0.82-0.95, p = 0.001), and employment status such as self-employed (aIRR 0.86, 95% CI; 0.76-0.97, p = 0.012) or unemployed (aIRR 0.86, 95% CI; 0.81-0.92, p < 0.01). Having an FVC-19S score below 21 was also a factor (aIRR 0.95, 95% CI; 0.90-1.00, p = 0.032).
conclusionsAlthough CRC screening rates increased from 2021 to 2022, a significant proportion of respondents still reported not undergoing screening, highlighting the importance of assessing the long-term impact of COVID-19 and identifying factors that make screening less accessible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.